Skip to content
Brand AI

Kunming Pharmaceutical Group

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2022

    Kunming Pharmaceutical wholly owned subsidiary penalized by Yunnan drug regulator for selling substandard Jiegu Qili Wan

    According to an administrative penalty decision by the Yunnan Provincial Medical Products Administration ((Yun) Yao Jian Yao Fa [2022] No. B29), Jiegu Qili Wan (batch No. 20211202) purchased from Luoyang Shunshi Pharmaceutical and sold by Kunming Pharmaceutical Group Pharmaceutical Commercial Co., Ltd., a wholly owned subsidiary of Kunming Pharmaceutical Group, failed to meet specifications in a national drug evaluation sampling test and was treated as a substandard drug. It had illegal gains of RMB 950 confiscated (other penalties were waived because it could prove it was unaware). Separately, according to company announcements, in 2015 the Yunnan Securities Regulatory Bureau issued a regulatory attention letter over errors in its 2014 annual report data; in 2020 the Shanghai Stock Exchange took regulatory attention measures against the company and its then board secretary. Status: administrative penalty. Entity involved: Kunming Pharmaceutical Group Pharmaceutical Commercial Co., Ltd. Scope: Kunming Pharmaceutical Commercial's drug operations.

    Source